Baird analyst Joel Beatty raised the firm’s price target on Immutep (IMMP) to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced investigator initiated INSIGHT-003 study data today for their lead agent eftilagimod alpha (efti).
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Immutep price target raised to $7 from $6 at Baird
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App